<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02801162</url>
  </required_header>
  <id_info>
    <org_study_id>PROXIMA</org_study_id>
    <nct_id>NCT02801162</nct_id>
  </id_info>
  <brief_title>Evaluation of Accuracy and Precision of a New Arterial Blood Gas Analysis System Blood in Comparison With the Reference Standard</brief_title>
  <official_title>Evaluation of Accuracy and Precision of the Proxima 3® (Sphere Medical) Arterial Blood Gas Analysis System in Comparison With the Reference Standard Hospital ABG in a Rapidly Changing Clinical Context</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the precision and accuracy of the Proxima 3® System by obtaining quantitative
      clinical data at various time points. Compare the methods associated with obtaining blood gas
      results using the Proxima 3® System device versus a conventional ABG analyse. The aim of the
      investigator is to evaluate the precision and accuracy of the Proxima 3® ABG system
      parameters (pH, pCO2 pO2, hematocrit and potassium) in clinical practices with rapid changing
      context.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the investigator will test the applicability of the Proxima 3® ABG system in a
      heterogeneous patient population consisting of patients scheduled for hybrid atrial
      fibrillation surgery, patients scheduled for heart valve surgery, complex cardiac surgery
      with deep cooling, spine surgery or patients with expected major blood loss. The investigator
      will compare the ABG values obtained with the traditional ABG measurement system of the
      hospital.

      The availability of a disposable patient-dedicated blood gas analyser allows rapid, frequent
      measurement of blood gases in theatre without the loss of theatre staff. As well as
      facilitating measurement in the unstable patient, this approach opens up the possibility for
      more frequent measurement to identify patient deterioration before a crisis occurs.

      The conventional laboratory ABG method uses sensor technology for pH, pCO2, pO2, sodium,
      potassium, calcium, glucose and lactate levels. It measures hemoglobin concentration via
      spectrophotometry methodology at a set wavelength of 467-672 nm. The blood gas laboratory
      uses ABL90 Flex (Radiometer®). The optical system is based on a 138-wavelength
      spectrophotometer with a measuring range of 467-672 nm. The spectrophotometer is connected
      via an optical fiber to a combined hemolyzer and measuring chamber.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of accuracy and precision of the Proxima 3® for ABG</measure>
    <time_frame>From intubation until extubation, max 1 day</time_frame>
    <description>Evaluate the precision and accuracy of the Proxima 3® System by obtaining quantitative clinical data at various time points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to obtain an arterial blood gas</measure>
    <time_frame>From intubation until extubation, max 1 day</time_frame>
    <description>Time for obtaining arterial blood gas: prelevation time to result time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hypoxia</condition>
  <condition>Hypercapnia</condition>
  <condition>Anaemia</condition>
  <arm_group>
    <arm_group_label>Conventional ABG analyser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Proxima 3® arterial blood gas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>conventional ABG analyser</intervention_name>
    <description>pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %</description>
    <arm_group_label>Conventional ABG analyser</arm_group_label>
    <arm_group_label>Proxima 3® arterial blood gas</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Proxima 3®</intervention_name>
    <description>pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %</description>
    <arm_group_label>Conventional ABG analyser</arm_group_label>
    <arm_group_label>Proxima 3® arterial blood gas</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients ≥18 years old

          -  Patients who have (or will have) an arterial line, which was (will be) inserted for
             clinical - need, will be considered for inclusion in this study

          -  Patients who give informed consent (or their personal/nominated consultee) to
             participate in the study

          -  Patients who are likely to have an arterial line for at least 6 hours.

        Exclusion Criteria:

          -  Patients contraindicated for an arterial line

          -  Refusal of consent by a patient

          -  Not for use with patients with uncorrected hyperphosphataemia, hypocalcaemia or
             hypercalcaemia.

          -  The patient is considered to be unsuitable for the study by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Umbrain, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Poelaert, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuella Martin, Apr. Biol.</last_name>
    <role>Study Chair</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Sneyers, Nurse</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriel Kotolácsi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Matagne, Nurse</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veerle Van Mossevelde, Data Nurse</last_name>
    <phone>+32 2 476 31 34</phone>
    <email>veerle.vanmossevelde@uzbrussel.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Jette</city>
        <state>Vlaams-Brabant</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veerle Van Mossevelde, Study Nurse</last_name>
      <phone>+32 2 476 31 34</phone>
      <email>veerle.vanmossevelde@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Jan Poelaert, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>June 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>December 7, 2016</last_update_submitted>
  <last_update_submitted_qc>December 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Veerle Van Mossevelde</investigator_full_name>
    <investigator_title>Data Nurse</investigator_title>
  </responsible_party>
  <keyword>arterial blood gas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Hypercapnia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

